Bivision

Bivision Pharmaceuticals, co-founded in 2021 by Dr. Haihua Yu, Dr. Yu Wang, and other biotech veterans, specializes in the development of novel targeted radiopharmaceuticals for cancer treatment. The company operates in the biopharmaceutical industry, focusing on visual diagnosis and treatment integrated nuclear drugs. Bivision's lead drug candidate, JH02, is a Lutetium-177 labeled small molecule ligand targeting Prostate Specific Membrane Antigen (PSMA) for treating metastatic castration-resistant prostate cancer (mCRPC). This drug has been approved by both the FDA and CDE and is currently in Phase I/II clinical trials. Bivision serves patients with advanced cancer, leveraging its proprietary technology platform to accelerate drug R&D programs to clinical stages more efficiently. The company generates revenue through the development and commercialization of its proprietary drugs, as well as potential partnerships and licensing agreements. Bivision's diversified R&D pipeline spans various stages of drug discovery and development, supported by a team with extensive experience in the pharmaceutical industry.

Keywords: radiopharmaceuticals, cancer treatment, visual diagnosis, targeted therapy, PSMA, mCRPC, Lutetium-177, clinical trials, proprietary technology, drug development.